Announcement • Sep 03

Asahi Kasei to Unveil Pfas-Free Polyamides and Cfrp Recycling Technology At K 2025

Asahi Kasei Corporation will unveil its newest innovation in PFAS-free polyamides and recycling technology of continuous carbon fibers at K 2025 in Hall 8a, Booth E23. The company will also showcase its diversified material solutions for automotive applications, improved connectivity and lightweighting. K 2025 is considered the world's No. 1 trade fair for plastics and rubber and will take place from October 8-15, 2025, in Düsseldorf, Germany. Asahi Kasei has developed a groundbreaking recycling technology that enables the recovery of continuous carbon fibers from CFRP (carbon fiber reinforced plastics) pressure vessels used in automobiles. Utilizing electrolyzed sulfuric acid, the process completely decomposes the resin matrix while preserving the carbon fibers' original strength and continuous structure. Unlike conventional recycling methods that result in chopped fibers, this technology allows for the perpetual recycling of high-quality, cost-effective continuous carbon fibers from CFRP pressure vessels. At the K Show, Asahi Kasei will showcase over 200 meters of recycled continuous carbon fiber. Asahi Kasei will also display PA and SEBS compounds utilizing a bio-based and biodegradable cellulose nano fiber (CNF). This material is made from cotton linter and has high heat resistance and network-forming ability. CNF-reinforced polyamide becomes less viscous when agitated, making it highly suitable for 3D printing applications for easy printing, dimensional accuracy, smooth appearance, and mechanical performance. CNF-reinforced SEBS features a unique softness, which can be adjusted by changing the internal structure of the molded product. In addition, it shows a very low warpage and shrinkage, and good hydrolysis resistance. These properties make this material suitable for a wide range of applications, for example, jigs & tooling or prosthetics & orthotics devices. In response to the increasing demand for PFAS-free materials, Asahi Kasei is developing a PFAS-free low-friction LEONA™ polyamide and will introduce the new grade for the first time in Europe. Based on internal evaluations, the material has the same low-friction properties as fluororesins, making it suitable for sliding applications in various industries, including automotive, robot parts, OA parts, and sporting goods. There has been a growing emphasis on reduced weight and improved design in automotive manufacturing. Asahi Kasei will display various technologies to address the most pressing concerns of automotive manufacturers at K 2025. One such solution is the transparent polymer, AZP™, which features an almost zero birefringence at a lightweight. It overcomes the challenges of conventional transparent polymers in applications with polarizing light, such as Virtual & Augmented Reality devices and automotive head-up displays (HUD), while maintaining superior processability for large-scale production of injection-molded optical components. The company will exhibit an interactive automotive demonstration at K 2025 to showcase how AZP™ contributes to next-generation HUD. Conventional approaches to automotive instrument panels, door panels, armrests, or center consoles have used different materials and production technologies for skin, foam, and core layers. Asahi Kasei’s SEBS material is suitable for skin and foam layers, which can be molded in one step by utilizing a core back injection molding process and the strong chemical bonding between all layers eliminates the need for additional adhesive layers. SEBS contributes to reducing the total number of materials, simplifying the manufacturing process, and improving the recyclability of interior components. Another solution to streamlining the manufacturing process for OEMs from Asahi Kasei is the mPPE (modified polyphenylene ether) particle foam, SunForce™. This material is well-suited for mass production of thin-walled, complex-shaped parts that require low tolerances, high heat stability, or UL94 V-0 flame retardancy. These properties make SunForce™ a perfect fit for thermal management solutions in electronic devices, transportation trays for Li-Ion battery cells, insulation parts for HVACs, and foam cores for FRP composite parts. With the increasing number of radar applications across industries, the pressure to reduce material, production costs, and weight is rising. Slotted waveguide array antennas for automotive millimeter-wave radars are typically made of metal, requiring cost- and time-intensive milling processes. Asahi Kasei’s mPPE XYRON™ features proven wet-platability, omitting the milling process and allowing for mass production of resin antenna parts via injection moulding which lowers cost and increases scalability. Asahi Kasei will exhibit in Hall 8a, Booth E23.

Announcement • May 30

Asahi Kasei Corporation (TSE:3407) made an offer to acquire Calliditas Therapeutics AB (publ) (OM:CALTX) from BVF Partners, Linc AB (publ), Stiftelsen Industrifonden and other shareholders for SEK 11.2 billion.

Asahi Kasei Corporation (TSE:3407) made an offer to acquire Calliditas Therapeutics AB (publ) (OM:CALTX) from BVF Partners, Linc AB (publ), Stiftelsen Industrifonden and other shareholders for SEK 11.2 billion on May 28, 2024. Under the terms, Asahi Kasei is acquiring all the outstanding shares of common stock, quota value of SEK 0.04 per share of Calliditas (the “Shares”) for SEK 208 in cash per Share (the “Offer”). The Offer also includes a concurrent offer by Asahi Kasei to acquire all outstanding American Depositary Shares of Calliditas, each representing two Shares (the “ADSs”) for SEK 416 in cash per ADS, which will be conducted pursuant to the securities rules of the United States. The total value of the Offer corresponds to SEK 11,164 million. Pursuant to the Offer, Asahi Kasei is expected to commence a tender offer on or around July 18, 2024, to acquire all of the outstanding Shares and ADSs of Calliditas. BVF Partners, Linc AB (publ) and Stiftelsen Industrifonden, the three largest Securityholders of Calliditas together with other large Securityholders, whose combined interest in the Company represents approximately 44.65 per cent3 of the total number of shares, have entered into undertakings with the Offeror to accept the Offer, subject to certain conditions. The Board has, as part of its process to evaluate the Offer and in line with its fiduciary duties, investigated other opportunities in light of the approach by the Offeror. The Board has been in contact with other potential bidders in order to evaluate a superior offer. The Board also notes that the Offer is not subject to any financing condition and the Offer consideration payable to shareholders and ADS holders of Calliditas that accept the Offer is financed in full by cash on hand. In the event that Asahi Kasei, whether in connection with the Offer or otherwise, becomes the owner of more than 90 per cent of the shares in Calliditas, Asahi Kasei intends to commence a compulsory buy-out procedure in respect of the remaining shares in accordance with the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)) as well as promote a delisting of the shares from Nasdaq Stockholm and the ADSs from Nasdaq Global Select Market. No commission will be charged by Asahi Kasei in respect of the settlement of the Offer. The Board of Directors of Calliditas Therapeutics AB (publ) unanimously recommends that the shareholders and holders of American Depositary Shares (“ADS”) of Calliditas Therapeutics AB (publ) (jointly the “Securityholders”) accept the public tender offer by Asahi Kasei Corporation. Completion of the Offer is conditional upon customary conditions including, amongst other things, the Tender Offer is subject to the tendering of at least 90% of the total outstanding shares of Calliditas common stock (excluding treasury shares) on a fully diluted basis the acceptance by shareholders owning > 90% of our shares and receipt of all necessary regulatory, governmental or similar clearances, approvals in France, Sweden, the United States and decisions, including from competition authorities and agencies screening foreign direct investments, in each case on terms that, in the Offeror’s opinion, are acceptable. Asahi Kasei has reserved the right to waive, in whole or in part, these and other conditions for completion of the Offer. Asahi Kasei has also reserved the right to shorten the acceptance period and set an earlier settlement date as well as to extend the acceptance period and to postpone the settlement date, as may be permissible under applicable laws and regulations. Calliditas not taking any action that is intended to impair the prerequisites for making or completing the Offer; and no other party announcing an offer to acquire shares or ADSs in Calliditas on terms that are more favourable to the shareholders or ADS holders of Calliditas than the terms of the Offer. The Offer requires filings under the U.S. Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended, as well as from agencies screening foreign direct investments such as the Swedish Inspectorate of Strategic Products and the Bureau Multicom 4 of the Ministry of Economy’s Treasury Department in France. The potential deal has been approved by the board of directors of the two companies. Asahi Kasei reserves the right to withdraw the Offer in the event that it is clear that any of the above conditions is not satisfied or cannot be satisfied. The transaction is expected to close in Q3, subject to any extensions. The acceptance period of the Offer is expected to commence on or around July 18, 2024 and expire on or around August 30, 2024, subject to any extensions. Asahi Kasei strongly believes this transaction will accelerate its transformation into a global specialty pharmaceutical business by unlocking the potential of existing business operations and human resources of Calliditas. Lazard AB (“Lazard”) is acting as financial advisor and provided fairness opinion to Calliditas and Advokatfirman Vinge KB (Swedish counsel) and DLA Piper LLP (US) (international counsel) are legal advisors to Calliditas in connection with the Offer. Lazard’s total fee as financial advisor is contingent on the size of the Offer consideration and whether the Offer is completed. Lazard will receive a fixed fee for providing this opinion, which is payable upon delivery of this opinion and creditable against Lazard’s total fee. MTS Health Partners LP and Goldman Sachs Japan Co., Ltd. are serving as the financial advisor to Asahi Kasei on the transaction. Fredrik Palm, Niclas Rockborn, Andreas Holmqvist and Foad Hoseinian, counsel Erika Olofsson of Gernandt & Danielsson Advokatbyrå and Cleary Gottlieb Steen & Hamilton are serving as the legal advisers to Asahi Kasei in connection with the transaction.

Total Shareholder Yield	2.5%
Future Dividend Yield	2.9%
Dividend Growth	5.7%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	36%

Segment	Dividend Yield
Company (3407)	2.5%
Market Bottom 25% (JP)	1.8%
Market Top 25% (JP)	3.9%
Industry Average (Chemicals)	2.1%
Analyst forecast (3407) (up to 3 years)	2.9%

Data	Last Updated (UTC time)
Company Analysis	2026/06/13 20:49
End of Day Share Price	2026/06/12 00:00
Earnings	2026/03/31
Annual Earnings	2026/03/31

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

Analyst	Institution
Mikiya Yamada	Barclays
Takashi Enomoto	BofA Global Research
Atsushi Ikeda	Citigroup Inc

Asahi Kasei Dividends and Buybacks

Dividend criteria checks 5/6

Key information

Recent dividend and buyback updates

Upcoming dividend of JP¥20.00 per share

Asahi Kasei (TSE:3407) Is Paying Out A Dividend Of ¥20.00

Asahi Kasei (TSE:3407) Is Due To Pay A Dividend Of ¥20.00

Asahi Kasei's (TSE:3407) Dividend Will Be ¥20.00

Asahi Kasei (TSE:3407) Is Due To Pay A Dividend Of ¥20.00

First half dividend of JP¥20.00 announced

Recent updates

Asahi Kasei Corporation to Report Q1, 2027 Results on Jul 31, 2026

Asahi Kasei Expands Acetolyte Reach With EAS Batteries Ultra-High-Power Cell Launch

Asahi Kasei Develops Novel Photosensitive Polyimide Film For Advanced Panel-Level Semiconductor Packaging

Asahi Kasei Corporation Plans to Streamline Operations At Its Mizushima Works by Fiscal 2030

Full year 2026 earnings: EPS exceeds analyst expectations

Asahi Kasei Corporation, Annual General Meeting, Jun 24, 2026

Asahi Kasei Corporation to Report Fiscal Year 2026 Results on May 12, 2026

Asahi Kasei Therapeutics Corp Initiates Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune Diseases

Upcoming dividend of JP¥20.00 per share

Asahi Kasei, Nippon Steel, and Nippon Steel Trading Launch Recycling Initiative for Pure Titanium Scrap in Electrolysis Cell Production

Price target increased by 7.5% to JP¥1,734

Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate into Phase I Study for the Treatment of Refractory Diseases

Asahi Kasei (TSE:3407) Is Paying Out A Dividend Of ¥20.00

Results: Asahi Kasei Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts

Third quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind

Asahi Kasei Corporation Revises Earnings Guidance for the Full Year Ending March 31, 2026

Asahi Kasei (TSE:3407) Is Due To Pay A Dividend Of ¥20.00

Asahi Kasei Develops Pfas-Free Pa66 Offering Low-Friction and High-Load Performance

Zoll Strengthens Growth Trajectory for Asahi Kasei's Healthcare Sector with U.S. Launch of the Next-Generation Lifevest®? Wcd

Asahi Kasei's (TSE:3407) Dividend Will Be ¥20.00

Asahi Kasei Corporation to Report Q3, 2026 Results on Feb 04, 2026

Asahi Kasei Strengthens Long-Term Profitability by Phasing Out HMD Production as Part of Structural Reform

Kingswood Capital Management, LP acquired Daramic, LLC from Asahi Kasei Corporation (TSE:3407).

Asahi Kasei (TSE:3407) Is Due To Pay A Dividend Of ¥20.00

Teijin Frontier Co., Ltd. concluded a basic agreement to acquire Asahi Kasei Advance Corporation from Asahi Kasei Corporation (TSE:3407).

First half dividend of JP¥20.00 announced

These 4 Measures Indicate That Asahi Kasei (TSE:3407) Is Using Debt Reasonably Well

Asahi Kasei Microdevices Showcases AgeTech and PetTech Solutions Combining Privacy and Convenience At CES 2026

Asahi Kasei Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Second quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind

Asahi Kasei Corporation Provides Earnings Guidance for the Full Year Ending March 31, 2026

Asahi Kasei Corporation (TSE:3407) agreed to acquire 14.01% stake in R. C. Core Co., Ltd. (TSE:7837).

Asahi Kasei Expands Healthcare Materials Portfolio with Sonanos™ Next-Generation Excipients

Upcoming dividend of JP¥20.00 per share

Asahi Kasei (TSE:3407) Will Pay A Dividend Of ¥20.00

Asahi Kasei to Unveil Pfas-Free Polyamides and Cfrp Recycling Technology At K 2025

Asahi Kasei (TSE:3407) Will Pay A Dividend Of ¥20.00

Asahi Kasei Successfully Demonstrates Biomethane Production with High Yield and High Purity Using Biogas from Organic Waste

Asahi Kasei Corporation Just Missed Earnings - But Analysts Have Updated Their Models

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Asahi Kasei Corporation to Report Q2, 2026 Results on Nov 05, 2025

Asahi Kasei (TSE:3407) Will Pay A Dividend Of ¥20.00

Asahi Kasei (TSE:3407) Will Pay A Dividend Of ¥20.00

Final dividend of JP¥20.00 announced

Full year 2025 earnings: EPS exceeds analyst expectations

New major risk - Revenue and earnings growth

Be Wary Of Asahi Kasei (TSE:3407) And Its Returns On Capital

Asahi Kasei Launches New Series of Sunfort™? Dry Film Photoresist as Material for Back-End Processing of Advanced Semiconductor Packaging Used in Ai Servers

Asahi Kasei Corp. Resolves to Discontinue Its Businesses for Methyl Methacrylate (Chma) Monomer, Cyclohexyl Methacrylate (Pmma) Resinomer) Resinomer, and to Reconfiguration of Acetonitrile Supply Framework for Acetonitrile

Full year 2025 earnings: EPS exceeds analyst expectations

Asahi Kasei Corporation, Annual General Meeting, Jun 25, 2025

Upcoming dividend of JP¥18.00 per share

Veloxis Pharmaceuticals and Asahi Kasei Company Receives Approval from USAN for "Pegrizeprument" as Nonproprietary Name for VEL-101

Third quarter 2025 earnings: EPS exceeds analyst expectations

Asahi Kasei Corporation to Report Fiscal Year 2025 Results on May 09, 2025

First half dividend of JP¥18.00 announced

Second quarter 2025 earnings: EPS misses analyst expectations

Asahi Kasei Corporation to Report Q3, 2025 Results on Feb 05, 2025

Upcoming dividend of JP¥18.00 per share

Asahi Kasei Launches New Grade of Lastan Flame-Retardant Nonwoven Fabric

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Asahi Kasei Corporation to Report Q2, 2025 Results on Nov 01, 2024

Final dividend of JP¥18.00 announced

Asahi Kasei Launches Membrane System to Produce Water for Injection

Asahi Kasei Micro Devices Launches CQ36 Series Integrated Circuit with Built-In DS Modulator

Less than half of directors are independent

Asahi Kasei Corporation (TSE:3407) made an offer to acquire Calliditas Therapeutics AB (publ) (OM:CALTX) from BVF Partners, Linc AB (publ), Stiftelsen Industrifonden and other shareholders for SEK 11.2 billion.

Asahi Kasei Corporation, Annual General Meeting, Jun 25, 2024

Asahi Kasei Corporation to Report Q1, 2025 Results on Jul 31, 2024